Figure 3

Macrophages were activated in the IMQ-treated skin of B6 mice. Mice were topically treated with a 60 mg daily topical dose of IMQ cream (5%). Mouse recombinant anti-mouse IL-17A was administered intraperitoneally (50 μg) once a day for a week in the IMQ-treated B6 mice. (A) Schema of intraperitoneal IL-17A injection and topical IMQ application protocol. (B) Immunohistochemistry of F4/80, iNOS, CX3CR1 and CD206 protein expression in the skin of B6 mice and IMQ-treated mice. Immunofluorescence co-staining images of iNOS (red), CX3CR1 (red) and CD206 (red) with F4/80 (green) and To-Pro-3 (blue) are shown. (C) Number of cells/HPF (×400). Due to the low expression of F4/80 protein in the skin of B6 mice, the F4/80 immunofluorescence signal of these mice is barely observed in the condition of this figure. (D) Representative Western blot results of F4/80, iNOS, CX3CR1, CD206 and β-actin are shown. (E) Densitometric analysis results were obtained from pooled data. Relative protein expression normalized to β-actin, arbitrary units. (F) Immunofluorescence co-staining images of phospho-STAT1 (red) or phospho-STAT3 (red) with F4/80 (green) and To-Pro-3 (blue). Due to the low expression of F4/80 protein in the skin of B6 mice, the F4/80 immunofluorescence signal of these mice is barely observed in the condition of this figure. (G) Representative Western blot results of phospho-STAT1, phospho-STAT3 and β-actin are shown. (H) Densitometric analysis results were obtained from pooled data. Relative protein expression normalized to β-actin, arbitrary units. Values represent the mean ± S.E. (n = 4–6). *P < 0.05. NS: not significant.